Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective observational study of stepwise drug treatment for post-bariatric hypoglycemia
NL-OMON20177Recruiting
- Sponsor
- cnter obesity north netherlands / medical center leeuwarden
- Start
- Mar 2020
- Modality
- Peptides, Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of acarbose, diazoxide, octreotide and liraglutide in post-bariatric hypoglycemia (PBH), sponsored by cnter obesity north netherlands / medical center leeuwarden. Primary endpoint: Control of hypoglycemic episodes leading to no interference in daily life. Started Mar 2020; status: recruiting.
02
Drugs
03
Conditions
post-bariatric hypoglycemia (PBH)
Beyond the preview
Go deeper on NL-OMON20177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20177.